AeroVironment reported strong Q4 results with earnings of $1.84 per share beating the $1.46 estimate and revenue doubling to $642 million, surpassing the $559 million forecast. The company's funded backlog rose to $1.2 billion, up 65% from last year, driven by growing global demand for drones, counter-drones, and space technology. Autonomous systems revenue notably exceeded expectations at $492 million versus $402 million predicted. CEO Wahid Nawabi highlighted that recent conflicts have accelerated the shift in warfare, positioning AeroVironment well for future growth.
Plum Acquisition Corp. IV has postponed its extraordinary general meeting of shareholders from July 2 to July 10, 2026, to allow more time for shareholder engagement. Consequently, the deadline for shareholders to submit redemption requests has been ...
The U.S. Supreme Court ruled in Chatrie v. U.S. that government collection of location data via geofence warrants constitutes a search under the Fourth Amendment. This decision overturns a lower court ruling and requires further review of whether the...
DBV Technologies is preparing to submit a Biologics License Application (BLA) for its VIASKIN® Peanut patch aimed at children aged 4 to 7 years. The company has engaged in detailed discussions with the FDA to ensure a thorough and efficient review pr...
Bron, a self-custody crypto wallet provider, has partnered with Noah, a global stablecoin payments infrastructure company, to enable seamless on- and off-ramp access for stablecoins. This integration allows Bron users to easily fund and withdraw from...
The FDA has approved Arcutis Biotherapeutics' ZORYVE cream 0.3% for treating plaque psoriasis in children aged 2 and older. This once-daily, non-steroidal topical treatment is safe, effective, and can be used on sensitive skin areas without duration ...
